Enroll in Research > Research Search & Enroll Tool > Using TAS-117 to Treat Advanced Solid Tumors with Inherited PTEN Mutations
Using TAS-117 to Treat Advanced Solid Tumors with Inherited PTEN Mutations

Using TAS-117 to Treat Advanced Solid Tumors with Inherited PTEN Mutations

Clinicaltrials.gov identifier:

Breast, Colorectal, Endometrial

Study Contact Information:

For additional information, please contact:

Osamu Takahashi, MD, PhD by phone: 609-250-7336 or by email at: clinicaltrialinfo@taihooncology.com

Treating Advanced Solid Tumors in People with Inherited PTEN Mutations Using the New Drug TAS-117

About the Study

This study will look at how well the targeted therapy TAS-117 works for treating people with an inherited PTEN mutation and advanced or metastatic solid tumors (excluding primary brain tumors).

Type of Study

This is an open-label, non-randomized study.

  • In this open-label study, all participants will receive the same medication.

What the Study Entails

All participants will receive TAS-117 orally every day or intermittently on a 21-day cycle.

Participants will be followed every 12 weeks for approximately 1 year, until disease progression, unacceptable toxicity, or a reason to discontinue treatment is met.

Study Sites


  • Santa Monica, CA
    Sarcoma Oncology Research Center                   

New York

  • New York, NY
    Memorial Sloan Kettering Cancer Center    


  • Cleveland, OH
    Cleveland Clinic Lerner Research Institute          


  • Philadelphia, PA
    Children's Hospital of Philadelphia  


  • Houston, TX
    The University of Texas M.D. Anderson Cancer Center        
This Study is Open To:

People may be eligible if they have the following:

  • Advanced solid tumor.
  • The disease has progressed after standard treatment for advanced or metastatic cancer or they couldn't tolerate or are ineligible for available standard therapies.
  • Age 12 or older (for patients between the ages of 12 and 18 they must have a body weight of at least 88 lbs).
  • Tested positive for an inherited PTEN mutation
This Study is Not Open To:

People cannot participate if they:

  • Have interstitial lung disease requiring steroid medication.
  • Are diabetic requiring insulin therapy.
  • Have had prior treatment with PI3K/AKT/mTOR pathway inhibitors.
  • Have a primary brain tumor.
  • Are receiving ≥10 mg/day of prednisone or its equivalent.